Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration

NCT01577381 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01577381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01577381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2012
Completion date
October 31, 2013
Enrollment
10 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

age-related maculopathy